Healthcare

Wall Street is split on the stock, and the shares are close to the average price target. Something's got to give.

The pharma company has agreed to cut some prices in exchange for an exemption from some levies.

Lilly is prepared to offer around $17.5 billion to acquire Abivax, a local media report suggests.

Moderna’s 2028 cash breakeven guidance may not be feasible, analysts say.

Vistra and Oklo stocks surge following agreements to provide nuclear power to Meta’s data centers.

Much of Gates’ optimism for the future rests on AI, although his annual look-ahead note warns of the technology’s potential negative effects.

Democrats forced a vote on a three-year extension of ACA premium subsidies. A bipartisan Senate group is working on its own, more limited deal—with abortion language as the key sticking point.

Lockheed Martin and Northrop Grumman rally after President Donald Trump says he would hike the defense budget to $1.5 trillion next year.

Neogen beat earnings estimates, raised its full-year revenue outlook, and has now posted back-to-back post-earnings stock spikes.

Shareholders in both drugmakers appear disappointed that a deal may not happen.

With tariff rules finalized and inventories depleted, there’s light at the end of the tunnel for the medical and scientific tools manufacturer.

Shares of Western Digital and Seagate Technology Holdings fall after racking up dazzling gains in the previous session.

BofA Securities upgrades shares to Buy from Hold with an $860 price target, up sharply from $627.

Arrowhead’s experimental therapy helped patients on Lilly’s Zepbound lose more weight and visceral fat—but cost and convenience could limit demand.

Nvidia’s next major AI chip in full production, gold, silver prices rise, Novo Nordisk starts new front in weight-loss drug fight, and more news to start your day.

The new CDC guidance recommends eight different vaccines to protect against 11 diseases. The prior schedule recommended 17 different shots.

With a 58% gain, CVS Health had its best year since 1982—and it wasn’t the only strong performer.

The biotech’s chief legal and financial officers were among four executives who sold shares on the same day.

Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly’s lead in obesity and diabetes treatment should hold for years.

The FDA cited insufficient evidence of effectiveness for relacorilant in patients with Cushing syndrome and hypertension, sending the stock sharply lower.

The FDA approved Vanda’s drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.

The Dogs of the Dow have their best year since 2019, more companies are expected to use AI in 2026, Lululemon founder aims to remake board, and more news to start your day.

Much in the new year depends on the fundamentals, which remain as complicated as ever. Watch these stocks.

At the current price, investors are paying little for Bristol Myers’ pipeline.